Endometrial Cancer

Regimen Options

Last Updated: 11/18/2024 See Details

	Evolent Pathways	Febrile Neutropenic Risk	Emetogenic Risk	References
Primary or Adjuvant	carboplatin and paclitaxel	Low	High	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Miller D, et al. Gynecol Oncol. 2012;125(3):771. Secord AA, et al. Gynecol Oncol. 2009;114(3):442-7. Fields AL, et al. Gynecol Oncol. 2008;108(1):201-6.
	carboplatin, paclitaxel and radiation	Low	High	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Lin LL, et al. Int J Radiat Oncol Biol Phys. 2016;95(1):181-9.
	carboplatin, paclitaxel and pembrolizumab except for carcinosarcoma	Low	High	NCCN Guidelines® for Uterine Neoplasms V.2.2023. Eskander RN et al. N Engl J Med 2023; 388:2159-2170
	carboplatin, paclitaxel and dostarlimab-gxly	Low	High	NCCN Guidelines® for Uterine Neoplasms V.2.2023. Mirza, MR et al. N Engl J Med 2023; 388:2145-2158
Advanced/Metastatic: Initial Therapy	carboplatin and paclitaxel	Low	High	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Miller D, et al. Gynecol Oncol. 2012;125(3):771. Secord AA, et al. Gynecol Oncol. 2009;114(3):442-7. Fields AL, et al. Gynecol Oncol. 2008;108(1):201-6.
	carboplatin, paclitaxel and pembrolizumab except for carcinosarcoma	Low	High	NCCN Guidelines® for Uterine Neoplasms V.2.2023. Eskander RN et al. N Engl J Med 2023; 388:2159-2170
	carboplatin, paclitaxel and dostarlimab-gxly	Low	High	NCCN Guidelines® for Uterine Neoplasms V.2.2023. Mirza, MR et al. N Engl J Med 2023; 388:2145-2158
Advanced/Metastatic: Subsequent Therapy	doxorubicin	Low	High	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Thigpen JT, et al. Cancer Treat Rep. 1979;63(1):21-7. Thigpen JT, et al. J Clin Oncol. 1994;12(7):1408-14.
	topotecan	High	Low	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Wadler S, et al. J Clin Oncol. 2003;21(11):2110-4.
	paclitaxel	Low	Low	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Dimopoulous MA, et al. Gynecol Oncol. 2000;78(1):52-7.
	carboplatin	Low	High	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Hoskins PJ, et al. J Clin Oncol. 2001;19(20):4048-53.
	cisplatin	Low	High	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Thigpen JT, et al. Gynecol Oncol. 1989;33(1):68-70.
	pembrolizumab (MSI-H/dMMR)	Low	Low	NCCN Guidelines® for Uterine Neoplasms V.3.2017. O'Malley DM et al. https://doi.org/10.1200/JCO.21.01874
	lenvatinib and pembrolizumab mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H)	Low	High	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Makker V et al. DOI: 10.1056/NEJMoa2108330
	carboplatin, paclitaxel and pembrolizumab except for carcinosarcoma	Low	High	NCCN Guidelines® for Uterine Neoplasms V.2.2023. Eskander RN et al. N Engl J Med 2023; 388:2159-2170
	carboplatin, paclitaxel and dostarlimab-gxly	Low	High	NCCN Guidelines® for Uterine Neoplasms V.2.2023. Mirza, MR et al. N Engl J Med 2023; 388:2145-2158
	carboplatin, paclitaxel and trastuzumab * stage III/IV or recurrent HER2 positive uterine serous carcinoma*	Low	Moderate	NCCN Guidelines® for Uterine Neoplasms V.3.2017. Fader AN et al. Clin Cancer Res 2020;26:3928–35
	Best Supportive Care or Clinical Trial	Not Applicable	Not applicable	Best Supportive Care or Clinical Trial

Primary or Adjuvant

Evolent Pathways

carboplatin and paclitaxel

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

carboplatin, paclitaxel and radiation

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

carboplatin, paclitaxel and pembrolizumab *except for carcinosarcoma*

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

carboplatin, paclitaxel and dostarlimab-gxly

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Advanced/Metastatic: Initial Therapy

Evolent Pathways

carboplatin and paclitaxel

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

carboplatin, paclitaxel and pembrolizumab *except for carcinosarcoma*

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

carboplatin, paclitaxel and dostarlimab-gxly

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Advanced/Metastatic: Subsequent Therapy

Evolent Pathways

doxorubicin

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

topotecan

Febrile Neutropenic Risk

high

Emetogenic Risk

low

References

Evolent Pathways

paclitaxel

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

carboplatin

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

cisplatin

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

pembrolizumab (MSI-H/dMMR)

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

lenvatinib and pembrolizumab *mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H)*

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

carboplatin, paclitaxel and pembrolizumab *except for carcinosarcoma*

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

carboplatin, paclitaxel and dostarlimab-gxly

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Evolent Pathways

carboplatin, paclitaxel and trastuzumab * stage III/IV or recurrent HER2 positive uterine serous carcinoma*

Febrile Neutropenic Risk

low

Emetogenic Risk

moderate

References

Evolent Pathways

Best Supportive Care or Clinical Trial

Febrile Neutropenic Risk

Emetogenic Risk

References

	Regimen	Alternative	References
LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES
	albumin-bound paclitaxel (Abraxane)	Alternative: paclitaxel

LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES

Regimen

** albumin-bound paclitaxel (Abraxane) **

Pathways and Low-Value Regimens

Endometrial Cancer